Mesdopetam is under clinical development by IRLAB Therapeutics and currently in Phase III for Drug-Induced Dyskinesia. According to GlobalData, Phase III drugs for Drug-Induced Dyskinesia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mesdopetam LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mesdopetam overview

Mesdopetam (IRL-790) is under development for the treatment of L-Dopa induced dyskinesias (LIDs). The drug candidate is a small molecule and a psychomotor stabilizer administered orally as a capsule. The drug candidate is based on integrative screening process (ISP) technology. It targets D3 dopamine receptor. It was also under development for the treatment of psychosis in Parkinson's disease (PD-P).

IRLAB Therapeutics overview

IRLAB Therapeutics (IRLAB) is a pharmaceutical company that discovers and develops central nervous system drugs primarily to assist patients with parkinson’s disease. The company uses its proprietary systems biology-based integrative screening process (ISP) research platform for the treatment of brain disorders. The company’s pipeline products include mesdopetam (IRL790), IRL942, IRL1117, pirepemat (IRL752) and IRL757. Its pipeline candidates treat levodopa (L-dopa) amino acid that dyskinesia induces in parkinson’s disease (PD-LIDs), injuries related to falls in parkinson’s disease (PD-Falls) and other neurological disorders. IRLAB is headquartered in Gothenburg, Vastra Gotaland, Sweden.

For a complete picture of Mesdopetam’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.